US Patent Issued to CNPharm on Sept. 23 for "Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity" (South Korean Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,961, issued on Sept. 23, was assigned to CNPharm Co. Ltd. (Seoul, South Korea).

"Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity" was invented by Hojun Kim (Seoul, South Korea) and Geun-Woo Jin (Seoul, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Synthesizing a docetaxel-aconitic anhydride conjugate using docetaxel, including: mixing aconitic anhydride with a chlorinating reagent to produce a first mixture; dissolving the first mixture in an organic solvent to produce a dissolved mixture; stirring the dissolved mixture; evaporating the organic solvent from the dissolved mixture to produce...